Sacubitril & Valsartan Tablets 49/51MG – WONMADA 100 Tablets

WONMADA 100 Tablets – Elevating Heart Failure Treatment with Dual Mechanism Action.

WONMADA 100 Tablets – The combination of Sacubitril & Valsartan Tablets 49/51MG contains Sacubitril, a neprilysin inhibitor, and Valsartan, an angiotensin II receptor blocker (ARB). This dual-action medication is specifically designed to manage heart failure with reduced ejection fraction (HFREF). Sacubitril enhances levels of beneficial peptides that promote blood vessel relaxation and sodium excretion, while Valsartan blocks angiotensin II, reducing vasoconstriction and blood pressure. Together, they provide comprehensive management of heart failure by reducing strain on the heart and improving cardiac function.

Key Benefits of sacubitril and valsartan tablets – WONMADA 100 Tablets
✅Dual Mechanism for Heart Failure Management – Combines neprilysin inhibition and angiotensin receptor blockade, addressing both volume overload and vascular resistance for optimal heart failure treatment.
✅Improved Mortality and Morbidity – Clinical trials show significant reduction in heart failure-related hospitalizations and mortality compared to ACE inhibitors, enhancing patient outcomes and quality of life.
✅Enhanced Symptom Relief – Provides better control of symptoms like fatigue, edema, and shortness of breath, allowing patients to maintain a more active lifestyle.

Recommended By Specialists:
👨‍⚕️Cardiologists: To primary prescribing in diagnosing and treating heart failure with reduced ejection fraction (HFrEF).
👨‍⚕️Internal Medicine Specialists: It is often initiate or continue therapy in stable heart failure patients.
👨‍⚕️General Physicians: To prescribes this composition for treating heart releated diseases.

INDICATIONS:
✅ Heart Failure (prevent hospitalization)
✅ Heart Failure with Reduced Ejection Fraction (HFREF)